Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

NCT05848219 · clinicaltrials.gov ↗
TERMINATED
Status
543
Enrollment
INDUSTRY
Sponsor class

Stopped Company decision

Conditions

Sponsor

Novartis Pharmaceuticals